Details

Autor(en) / Beteiligte

• Xu, Dao-zhen
• Cai, Hao-dong
• Ma, Xiu-yun
• Li, Yue-qi
• Lu, Xian-zhong
• Yu, Hai-ying
• Sun, Ai-min
• Zhao, Long-feng
• Zhang, Liao-yun
• Gao, Xiao-hong

Titel

Comparative analysis of the efficacies of entecavir capsules and lamivudine in chronic hepatitis B patients

Ist Teil von

• Zhonghua gan zang bing za zhi, 2013-12, Vol.21 (12), p.886

Ort / Verlag

China

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• To investigate the efficacy profile of entecavir capsule (ETV) as a chronic hepatitis B therapy, as compared to lamivudine (LAM). In this multicenter, randomized, double-blind, parallel group evaluation of ETV, 232 subjects were administered a 96-week course of 0.5 mg/day ETV or 100 mg/day LAM. PCR measurement of hepatitis B virus (HBV) was conducted throughout the treatment course to determine achievement of complete virologic response (CVR; defined as less than 500 copies/ml of HBV DNA) or experience of virology rebound ( more than 500 copies/ml of HBV DNA after achievement of CVR). After week-48 of treatment, the ETV group showed a higher CVR rate (90.3% vs. LAM: 59.4%) and lower virology rebound rate (1.9% vs. LAM: 13.9%). After week-96 of treatment, the ETV group continued to have a higher CVR rate (86.0% vs. LAM: 71.4%), and virology rebound was experienced by significantly less subjects in the ETV group (1.2% vs. LAM: 11.9%, P = 0.005). ETV therapy can quickly and continuously suppress HBV replication